Abstract:INTRODUCTION: Stroke is a leading cause of death and long-term disability worldwide. Acute ischemia results in a profound inflammatory response that is counterproductive to short- and long-term recovery. Programmed Death Protein 1 (PD-1) is an immune checkpoint that has been shown to be upregulated after acute cerebral injury, and—upon binding its ligand PD-L1—negatively regulates immune cells to limit the inflammatory response. METHODS: C57BL/6J mice underwent middle cerebral artery occlusion (MCAO) and were randomized into three arms: (1)sham surgery, (2)MCAO control, and (3)MCAO+PD-L1. Survival, brain water content, and volumetric MRI analysis of cerebral edema were measured. Brains were analyzed by flow cytometry to quantify PD-1 expression on infiltrating immune cells. Peripheral blood was harvested for single-cell RNA-sequencing. Blood from stroke patients was collected, and the frequency of PD-1+ monocytes was correlated to clinical outcomes. RESULTS: PD-L1 significantly decreased brain edema as measured by brain water content (p = 0.0277) and high-resolution MRI (p < 0.0001), and improved overall survival (p = 0.0022). PD-1+ monocytes are upregulated in the ischemic hemisphere, and appear to be critical mediators of edema. PD-L1 treatment decreased PD-1+ monocyte infiltration , while global PD-1 (PD-1-/-) and myeloid-specific knockout of PD-1 (PD-1f/fLysMcre) abrogated the treatment effect on edema. Single-cell RNA sequencing and differential expression analysis of peripheral monocytes revealed downregulation of multiple pro-inflammatory pathways in the treated mice versus the controls. Human correlative studies confirmed that PD-1+ monocytes were present in the peripheral blood of MCA stroke patients, and the frequency of this cell population correlated with post-stroke cerebral edema. CONCLUSIONS: Our results support PD-L1 as a novel therapeutic strategy for neuroinflammation and cerebral edema after acute ischemic stroke.

PD-1/PD-L Axis in Neuroinflammation: New Insights

Emerging Role of PD-1 in the Central Nervous System and Brain Diseases

PD-1/PD-L1 in disease

PD-1 regulation in immune homeostasis and immunotherapy

Therapeutic implications for the PD-1 axis in cerebrovascular injury

Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors

Immune checkpoint inhibitors and neurotoxicity: a focus on diagnosis and management for a multidisciplinary approach

The role of PD-1 signaling in health and immune-related diseases

159 PD-1 Agonism as a Strategy to Prevent Neuroinflammation After Acute Large Vessel Occlusion

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PDL1 blockade

Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy

Delicate Role of PD-L1/PD-1 Axis in Blood Vessel Inflammatory Diseases: Current Insight and Future Significance

Current studies and future promises of PD-1 signal inhibitors in cervical cancer therapy

The immune regulation of PD-1/PDL-1 axis, a potential biomarker in multiple sclerosis

New Immunotherapies Targeting the PD-1 Pathway.

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

Emerging concepts in PD-1 checkpoint biology

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells

PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders